Dr. Reddy's Partners with Henlius on $131.6M Cancer Drug License

Shanghai Henlius Biotech has entered a licensing agreement with Dr. Reddy's Laboratories for HLX15, a biosimilar candidate to Darzalex, which is a treatment for multiple myeloma. This investigational drug is a fully human monoclonal antibody available in both intravenous and subcutaneous formulations. Under the deal, which could be worth up to $131.6 million, Henlius will handle the development and manufacturing, while Dr. Reddy's secures exclusive commercialization rights in the U.S. and 42 European countries. Henlius aims to enhance its global market competitiveness through this partnership, addressing unmet medical needs in oncology. Both companies view this collaboration as a strategic step towards improving patient access to advanced biologics. The partnership reflects Dr. Reddy's ongoing commitment to oncology as a key therapeutic area.